Vedolizumab Drug Aliquot | Anti-α4β7integrin | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Vedolizumab are now available as research consumables.

Vedolizumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Vedolizumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Entyvio Vedolizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Entyvio® / Vedolizumab

Drug nameEntyvio®
INNVedolizumab
API typeVedolizumab is a humanised IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic groupImmunosuppressants, selective immunosuppressants
ATC codeL04AA33
Target of antibodyα4β7 integrin
General functionVedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Entyvio is also indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Vedolizumab is a gut-selective immunosuppressive biologic. It is a humanised monoclonal antibody that binds specifically to the α4β7 integrin, which is preferentially expressed on gut homing T helper lymphocytes. By binding to α4β7 on certain lymphocytes, vedolizumab inhibits adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1). MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to tissues within the gastrointestinal tract. Vedolizumab does not bind to, nor inhibit function of, the α4β1 and αEβ7 integrins.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects
and in patients with moderate to severely active ulcerative colitis or Crohn’s disease
Original license holder
Marketing authorisation numbersEU/1/14/923/002
Marketing authorisation holderTakeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark
Name of the manufacturer of the biological active substanceAbbVie Bioresearch Center 100 Research Drive Worcester, MA 01605-4314 USA; Abbvie Biotechnology, Ltd Road #2 Km 59.2 PO Box 2191 Barceloneta Puerto Rico 00617; Lonza Biologics, Inc. 101 International Drive Portsmouth NH 03801 USA
Name and address of the manufacturer(s) responsible for batch releaseDelpharm Novara S.r.l. Via Crosa, 86 28065 Cerano (NO) Italy; Takeda Austria GmbH St. Peter-Straße 25 4020 Linz Austria
Max shelf life24 months
Storage conditions2 °C-8 °C
List of excipientsCitric acid monohydrate - Sodium citrate dihydrate - L-histidine - L-histidine monohydrochloride - L-arginine hydrochloride - Polysorbate 80 - Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.